1. Antiplatelet drugs Antiplatelet drugs are recommended in most cases to prevent ischemic stroke and TIA recurrence. The choice of antiplatelet drugs is based on monotherapy, with clopidogrel (Poliovir 75 mg/d) and aspirin (50-325 mg/d) as the drugs of choice. 2, hypertension: for every 10 mm Hg increase in systolic blood pressure, the relative risk of stroke increases by 49%, and for every 5 mm Hg increase in diastolic blood pressure, the risk of stroke increases by 46%. 2002 survey, the Chinese population hypertension awareness rate is only 30.2%, treatment rate is 24.7%, control rate is 6.1%, which is at a poor level. In reference to advanced age, basal blood pressure, usual medication and tolerability, the goal of blood pressure lowering should generally reach ≤140/90 mm Hg, and ideally should reach ≤130/80 mm Hg. In terms of reducing stroke events, calcium antagonists can better reduce stroke events. 3. Diabetes: The target goal for glycemic control in diabetes is HbAlc < 6. 5%, but for high-risk type 2 diabetic patients hypoglycemia may pose a hazard. When diabetes is combined with hypertension, blood pressure lowering drugs such as angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists are of significant benefit in reducing cardiovascular and cerebrovascular events. 4. Abnormal lipid metabolism: Patients with ischemic stroke and TIA with elevated cholesterol levels should undergo lifestyle intervention and pharmacological treatment. Statins are recommended, with the goal of reducing LDL-C levels to below 2.59 mmol/L or achieving a 30-40% reduction in LDL-C. Patients with ischemic stroke and TIA with multiple risk factors (coronary artery disease, diabetes mellitus, unabated smoking, metabolic syndrome, cerebral atherosclerotic lesions without definite evidence of vulnerable plaque or arterial-derived embolism, or one of the peripheral arterial diseases) who have LDL-C > 2.07 mmol/L should reduce LDL-C to less than 2. 07 mmol/L or achieve an LDL-C down by >40%. Long-term use of statins is generally safe. Clinical symptoms such as myalgia and changes in liver enzymes (glutamate and aspartate aminotransferase) and muscle enzymes (creatine kinase) should be monitored regularly before and during statin therapy, and the dose should be reduced or discontinued for observation if there are persistent abnormalities in the monitored indicators and other influencing factors are excluded (discontinuation of the drug should be observed when liver enzymes are >3 times the upper limit of normal and muscle enzymes are >5 times the upper limit of normal).